Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Bio-Techne

Bio-Techne Corporation is a developer and manufacturer of high-quality purified proteins and reagent solutions - nota... read more Featured Products: More products

Download Mobile App




Benchtop Automated ELISA Platform Achieves Consistent Biomarker Detection

By LabMedica International staff writers
Posted on 06 Apr 2023
Print article
Image: More than 1,000 Ella instruments are now in operation (Photo courtesy of Bio-Techne)
Image: More than 1,000 Ella instruments are now in operation (Photo courtesy of Bio-Techne)

There is growing demand across the scientific and clinical research fields for an immunoassay solution that is both fast and efficient, while ensuring precise and reliable analysis of biomarkers. Furthermore, researchers aim for a higher analysis speed, producing fully analyzed data in less time without sacrificing long-term consistency. Automation offers an opportunity to enhance the efficiency of critical quality steps throughout the discovery to commercialization continuum, while reducing sources of variability and operator bias to provide more accurate and reliable results.

The Ella automated immunoassay instrument from Bio-Techne Corporation (Minneapolis, MN, USA) streamlines the laborious manual process associated with traditional immunoassays, delivering quicker results, increased lab efficiency and reduced human error. The automation of key steps in the assay workflow ensures high levels of reproducibility and data quality, which are crucial factors in research and translational applications.

Manufactured under Bio-Techne's ProteinSimple brand, Ella represents a significant advancement in immunoassays. In less than 90 minutes, it delivers highly reproducible assay data with consistent biomarker detection, and without the need for any manual steps. The assay performance behind that data includes sub-picogram level sensitivity, 4+ logs of dynamic range, and precision which equals the best laboratory automation. With an expanding assay menu of over 250 analytes, Ella supports therapeutic areas across neuroscience, cell and gene therapy, immunology, and cancer. Bio-Techne has achieved a significant milestone, with over 1,000 Ella automated immunoassay instruments now in use.

"We are proud of Ella's contributions towards our mission to catalyze advances in science and medicine." said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We look forward to celebrating new milestones in the future with Ella as the underlying need for greater analytical speed, precision, and reproducibility remains a core driver across clinical and research sectors."

Related Links:
Bio-Techne Corporation

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.